Search

Your search keyword '"Flock F"' showing total 116 results
Start Over Author "Flock F"
116 results on '"Flock F"'

2. Inwieweit fühlen sich die Brustkrebs-Überlebenden 5 Jahre nach der Diagnose gut über die Krankheit und die Behandlung informiert?

Author

Herbert, L S, additional, Wöckel, A, additional, Kreienberg, R, additional, Kühn, T, additional, Flock, F, additional, Felberbaum, R, additional, Janni, W, additional, Curtaz, CJ, additional, Kiesel, M, additional, Schlaiß, T, additional, Diessner, J, additional, Salmen, J, additional, Schwentner, L, additional, Fink, V, additional, Bekes, I, additional, Leinert, E, additional, Lato, K, additional, Polasik, A, additional, Schochter, F, additional, and Singer, S, additional

Published
2022
Full Text
View/download PDF

3. Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers

Author

Ortmann, Olaf, Blohmer, J.-U., Sibert, N. T., Brucker, S., Janni, W., Wöckel, A., Scharl, A., Dieng, S., Ferencz, J., Inwald, E. C., Wesselmann, S., Kowalski, C., Denisjuk, E., Csorba, R., Rezek, D., Peschel, S., Denschlag, D., Schad, F., Dieterle, D., Lex, B., Rieger, L., Flock, F., Cramer, A., Strittmatter, H.-J., Bettscheider, J., Lindner, C., Stefek, A., Pauker, W., Hönig, A., Schrauder, M., Seeger, D., Kleine-Tebbe, A., Bleimehl, A., Groh, U., Gebauer, G., Vollert, H.-W., Zorr, A., Friedmann, W., Krabisch, P., Fritz, S., Schwämmle, A., Lucke, W., Schmatloch, S., Heyl, W., Deuschle, P., Arfsten, M., Scheler, P., Ruf-Dördelmann, A., Brückner, B., Bauer, L., Koch, M., Monner, J., Nixdorf, A., Merte, A., Beldermann, F., Felberbaum, R., De Wilde, R. L., Bolkenius, P., Lebrecht, A., Solomayer, E.-F., Hartmann, S., and Hartkopf, A.

Subjects
ddc:610, Early breast cancer · Neoadjuvant chemotherapy · Breast cancer centers · Guidelines · Oncobox research, 610 Medizin, skin and connective tissue diseases
Abstract

Neoadjuvant chemotherapy (NACT) is frequently used in patients with early breast cancer. Randomized controlled trials have demonstrated similar survival after NACT or adjuvant chemotherapy (ACT). However, certain subtypes may benefit more when NACT contains regimes leading to high rates of pathologic complete response (pCR) rates. In this study we analyzed data using the OncoBox research from 94,638 patients treated in 55 breast cancer centers to describe the current clinical practice of and outcomes after NACT under routine conditions. These data were compared to patients treated with ACT. 40% of all patients received chemotherapy. The use of NACT increased over time from 5% in 2007 up to 17.3% in 2016. The proportion of patients receiving NACT varied by subtype. It was low in patients with HR-positive/HER2-negative breast cancer (5.8%). However, 31.8% of patients with triple-negative, 31.9% with HR-negative/HER2-positive, and 26.5% with HR-positive/HER2-positive breast cancer received NACT. The rates of pCR were higher in patients with HR-positive/HER2-positive, HR negative/HER2-positive and triple-negative tumors (36, 53 and 38%) compared to HR-positive/HER2-negative tumors (12%). PCR was achieved more often in HER2-positive and triple-negative tumors over time. This is the largest study on use and effects of NACT in German breast cancer centers. It demonstrates the increased use of NACT based on recommendations in current clinical guidelines. An improvement of pCR was shown in particular in HER2-positive and triple-negative breast cancer, which is consistent with data from randomized controlled trails.

Published
2022

13. Running injuries: an epidemiological study

Author

Listabarth, S, Benca, E, Florian Flock, F, Pablik, E, Walzer, S, Dorotka, R, Windhager, R, and Ziai, P

Subjects
Injuries, ddc: 610, Epidemiology, 610 Medical sciences, Medicine, Sports Medicine, human activities, Running
Abstract

Objectives: Running is one of the most popular physical activities worldwide. Besides its obvious benefits, it is associated with injuries (running related injuries or RRI). It remains unclear which key factors act predisposing or protective of RRI. It is very likely that the aetiology of RRI is complex[for full text, please go to the a.m. URL], Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2018)

Published
2018
Full Text
View/download PDF

14. Das BRandO Biology and Outcome (BiO)-Projekt – eine Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei Mamma- und Ovarialkarzinomen (BReast and Ovarian Cancer)

Author

de Gregorio, A, additional, Nagel, G, additional, Rothenbacher, D, additional, Möller, P, additional, Rempen, A, additional, Schlicht, E, additional, Fritz, S, additional, Flock, F, additional, Felberbaum, R, additional, Friedl, TWP, additional, Thiel, F, additional, Kühn, T, additional, Kuhn, P, additional, Tzschaschel, M, additional, Janni, W, additional, Wiesmüller, L, additional, and Huober, J, additional

Published
2019
Full Text
View/download PDF

15. Das BRandO biology and outcome (BiO)-projekt – eine Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei Mamma- und Ovarialkarzinomen

Author

de Gregorio, A, additional, Nagel, G, additional, Kühn, T, additional, Rempen, A, additional, Schlicht, E, additional, Fritz, S, additional, Flock, F, additional, Felberbaum, R, additional, Friedl, TW, additional, Kuhn, P, additional, Bekes, I, additional, Ernst, K, additional, Schochter, F, additional, Janni, W, additional, Wiesmüller, L, additional, and Huober, J, additional

Published
2019
Full Text
View/download PDF

16. Abstract OT1-11-01: The BRandO BiO registry – A multicenter regional registry for patients with primary breast and ovarian cancer with longitudinal biobanking and evaluation of epidemiological, life style and quality of life factors

Author

Huober, J, primary, Nagel, G, additional, Rempen, A, additional, Schlicht, E, additional, Flock, F, additional, Fritz, S, additional, Thiel, F, additional, Wiesmüller, L, additional, Felderbaum, R, additional, Heilmann, V, additional, Bekes, I, additional, Fink, V, additional, Albrecht, S, additional, De Gregorio, N, additional, Tzschaschel, M, additional, Ernst, K, additional, Wolf, C, additional, Kuhn, P, additional, Friedl, T, additional, Janni, W, additional, and De Gregorio, A, additional

Published
2019
Full Text
View/download PDF

17. To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?

Author

Herbert, S. L., Wöckel, A., Kreienberg, R., Kühn, T., Flock, F., Felberbaum, R., Janni, W., Curtaz, C., Kiesel, M., Stüber, T., Diessner, J., Salmen, J., Schwentner, L., Fink, V., Bekes, I., Leinert, E., Lato, K., Polasik, A., Schochter, F., and Singer, S.

Abstract

Objective: In this study, we investigated to which extent patients feel well informed about their disease and treatment, which areas they wish more or less information and which variables are associated with a need for information about the disease, medical tests and treatment. Methods: In a German multi-centre prospective study, we enrolled 759 female breast cancer patients at the time of cancer diagnosis (baseline). Data on information were captured at 5 years after diagnosis with the European Organisation for Research and Treatment of Cancer (EORTC) Information Module (EORTC QLQ-INFO24). Good information predictors were analysed using linear regression models. Results: There were 456 patients who participated at the 5-year follow-up. They reported to feel well informed about medical tests (mean score 78.5) and the disease itself (69.3) but relatively poorly about other services (44.3) and about different places of care (31.3). The survivors expressed a need for more information concerning: side effects and long-term consequences of therapy, more information in general, information about aftercare, prognosis, complementary medicine, disease and therapy. Patients with higher incomes were better informed about medical tests (β 0.26, p 0.04) and worse informed with increasing levels of fear of treatment (β − 0.11, p 0.02). Information about treatment was reported to be worse by survivors > 70 years old (β -0.34, p 0.03) and by immigrants (β -0.11, p 0.02). Survivors who had received additional written information felt better informed about disease, medical tests, treatment and other services (β 0.19/0.19/0.20/0.25; each p < 0.01). Conclusion: Health care providers have to reconsider how and what kind of information they provide. Providing written information, in addition to oral information, may improve meeting those information needs. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

19. Das BRandO Biology and Outcome (BiO)-Projekt – eine Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei Mamma- und Ovarialkarzinomen (BReast and Ovarian Cancer)

Author

de Gregorio, A, additional, Nagel, G, additional, Rothenbacher, D, additional, Möller, P, additional, Rempen, A, additional, Schlicht, E, additional, Fritz, S, additional, Flock, F, additional, Felberbaum, R, additional, Friedl, TWP, additional, Kuhn, P, additional, Tzschaschel, M, additional, Janni, W, additional, Wiesmüller, L, additional, and Huober, J, additional

Published
2018
Full Text
View/download PDF

20. Erste epidemiologische Daten zum Patientenkollektiv des BRandO Biology and Outcome (BiO)-Projekts (BReast and Ovarian Cancer)

Author

de Gregorio, A, additional, Rempen, A, additional, Schlicht, E, additional, Fritz, S, additional, Flock, F, additional, Kühn, T, additional, Thiel, F, additional, Felberbaum, R, additional, Kuhn, P, additional, Rothenbacher, D, additional, Albrecht, S, additional, Ernst, K, additional, Schochter, F, additional, Tzschaschel, M, additional, Friedl, TWP, additional, Möller, P, additional, Janni, W, additional, Huober, J, additional, and Nagel, G, additional

Published
2018
Full Text
View/download PDF

21. Erste epidemiologische Ergebnisse des BRandO-Biology and Outcome (BiO)-Projekts – einer Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei Mamma- und Ovarialkarzinomen (BReast and Ovarian Cancer)

Author

de Gregorio, A, additional, Möller, P, additional, Rothenbacher, D, additional, Rempen, A, additional, Schlicht, E, additional, Fritz, S, additional, Flock, F, additional, Kühn, T, additional, Thiel, F, additional, Felberbaum, R, additional, Kuhn, P, additional, Tzschaschel, M, additional, Friedl, T, additional, Janni, W, additional, Huober, J, additional, and Nagel, G, additional

Published
2018
Full Text
View/download PDF

22. Abstract P6-17-08: Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 548 patients from the multicenter registry

Author

Witzel, I, primary, Loibl, S, additional, Laakmann, E, additional, Augustin, D, additional, Flock, F, additional, Dohmen, H-H, additional, Durmus, G, additional, Frank, M, additional, Hesse, T, additional, Ignatov, A, additional, Kühn, T, additional, Neunhöffer, T, additional, Park-Simon, T-W, additional, Schmidt, M, additional, Stefek, A, additional, Weide, R, additional, Würschmidt, F, additional, Fehm, T, additional, Moebus, V, additional, von Minckwitz, G, additional, Burchardi, N, additional, and Mueller, V, additional

Published
2016
Full Text
View/download PDF

23. Therapie-Ängste von Mammakarzinom-Patientinnen

Author

Vorwerk, E, primary, Gundelach, T, additional, Schwentner, L, additional, Wolfgang, J, additional, Kreienberg, R, additional, Wöckel, A, additional, Kühn, T, additional, Felberbaum, R, additional, Flock, F, additional, Blettner, M, additional, and Singer, S, additional

Published
2015
Full Text
View/download PDF

27. Transpacific transport of ozone pollution and the effect of recent Asian emission increases on air quality in North America: an integrated analysis using satellite, aircraft, ozonesonde, and surface observations

Author

Zhang, L., primary, Jacob, D. J., additional, Boersma, K. F., additional, Jaffe, D. A., additional, Olson, J. R., additional, Bowman, K. W., additional, Worden, J. R., additional, Thompson, A. M., additional, Avery, M. A., additional, Cohen, R. C., additional, Dibb, J. E., additional, Flock, F. M., additional, Fuelberg, H. E., additional, Huey, L. G., additional, McMillan, W. W., additional, Singh, H. B., additional, and Weinheimer, A. J., additional

Published
2008
Full Text
View/download PDF

46. Diagnostische Wertigkeit von Sonographie, Kernspintomographie und Positronenemissionstomographie zur Beurteilung der Dignität von Adnextumoren bei prämenopausalen Patientinnen - Premenopausal Adnex Masses: Diagnostic Accuracy of Sonography, Magnetic Resonance Imaging, and Positron Emission Tomography -

Author

Grab, D., primary, Flock, F., additional, Stöhr, I., additional, Rieber, A., additional, Nüssle, S., additional, Brambs, H. J., additional, Fenchel, S., additional, Reske, S. N., additional, and Kreienberg, R., additional

Published
2000
Full Text
View/download PDF

50. Free Thyroxine Level in the High Normal Reference Range Prescribed for NonpregnantWomenMay Reduce the PretermDelivery Rate inMultiparous.

Author

Torremante, P., Flock, F., and Kirschner, W.

Subjects
*MORTALITY, *THYROXINE, *RETROSPECTIVE studies, *CONTROL groups, *SCIENTIFIC observation, *DELIVERY (Obstetrics)
Abstract

Preterm birth is the most common reason for perinatal morbidity and mortality in the western world. It has been shown that in euthyreotic pregnant women with thyroid autoimmune antibodies, L-Thyroxine replacement reduces preterm delivery rate in singleton pregnancies. We investigated in a nonrandomized retrospective observational study whether L-Thyroxine replacement, maintaining maternal free thyroxine serum level in the high normal reference range prescribed for nonpregnant women also influences the rate of preterm delivery in women without thyroid autoimmune antibodies. As control group for preterm delivery rate, data from perinatal statistics of the State of Baden-Württemberg from 2006 were used. The preterm delivery rate in the study group was significantly reduced. The subgroup analysis shows no difference in primiparous but a decline in multiparous by approximately 61% with L-Thyroxine replacement. Maintaining free thyroxine serum level in the high normal reference range prescribed for nonpregnant women may reduce the preterm delivery rate. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results